US Stock MarketDetailed Quotes
TAK Takeda Pharmaceutical
- 13.570
- +0.130+0.97%
Close Nov 27 16:00 ET
- 13.990
- +0.420+3.10%
Post 16:38 ET
43.18BMarket Cap22.85P/E (TTM)
13.630High13.490Low2.24MVolume13.490Open13.440Pre Close30.42MTurnover0.07%Turnover Ratio45.54P/E (Static)3.18BShares15.08052wk High0.96P/B41.32BFloat Cap12.57552wk Low0.31Dividend TTM3.05BShs Float20.357Historical High2.27%Div YieldTTM1.04%Amplitude11.568Historical Low13.579Avg Price1Lot Size
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Company Profile
SymbolTAK
Company NameTakeda Pharmaceutical
Listing DateDec 24, 2018
Founded1781
CEOMr. Christophe Weber
MarketNYSE
Employees49281
Securities TypeDR
ADS Ratio2.0 : 1.0
Fiscal Year Ends03-31
Address4-1-1 Dosho-machi,Chuo-Ku
CityOsaka
ProvinceOsaka
CountryJapan
Zip Code540-8645
Phone81-6-6204-2111
Websitehttp://www.takeda.com
Company Executives
- Name
- Position
- Salary
- Akiko Amakawa
- Corporate Strategy Officer and Chief Executive Officer Chief of Staff
- --
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
- 1.70B
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Milano Furuta
- Director and Chief Financial Officer
- --
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Lauren Duprey
- Chief Human Resources Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Elaine Shannon
- Global Quality Officer
- --
- Teresa Marie Bitetti
- President, Global Oncology Business Unit
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Asuka Miyabashira
- President, Japan Pharma Business Unit
- --
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 12.00M
- Yoshiaki Fujimori
- Independent Director
- 40.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 44.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Miki Tsusaka
- Independent Director
- 32.00M
- Emiko Higashi
- Independent Director
- 49.00M
- Kimberly A. Reed
- Independent Director
- 41.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Ian T. Clark
- Independent Director
- 44.00M
- Michel Orsinger
- Independent Director
- 46.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 39.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
